Presence of membrane-bound TGF-β1 and its regulation by IL-2-activated immune cell-derived IFN-γ in head and neck squamous cell carcinoma cell lines

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6114-6120

  Ahn, Yong Oon ^a   Lee, June Chul ^a   Sung, Myung Whun ^a   Heo, Dae Seog ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CYCLOHEXIMIDE; DACTINOMYCIN; GAMMA INTERFERON; INTERLEUKIN 2; LATENCY ASSOCIATED PEPTIDE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; PRECURSOR; PRIORITY JOURNAL; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA; SYNTHESIS; TUMOR IMMUNITY; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952337131     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803725     Document Type: Article

References (48)

1. Gandhi, R., D. E. Anderson, and H. L. Weiner. 2007. Cutting edge: immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-β-dependent manner. J. Immunol. 178: 4017-4021. (Pubitemid 46492348)
2. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553. (Pubitemid 47041228)
3. Wikstrom, P., P. Stattin, I. Franck-Lissbrant, J. E. Damber, and A. Bergh. 1998. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29. (Pubitemid 28385181)
4. Hasegawa, Y., S. Takanashi, Y. Kanehira, T. Tsushima, T. Imai, and K. Okumura. 2001. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964-971.
5. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335-7340.
6. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125. (Pubitemid 36418167)
7. Thomas, D. A., and J. Massague. 2005. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
8. Wrzesinski, S. H., Y. Y. Wan, and R. A. Flavell. 2007. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13: 5262-5270. (Pubitemid 47510349)
9. Jakowlew, S. B. 2006. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev. 25: 435-457. (Pubitemid 44922360)
10. Turley, E. A., M. Veiseh, D. C. Radisky, and M. J. Bissell. 2008. Mechanisms of disease: epithelial-mesenchymal transition: does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5: 280-290.
11. Kim, S. J., Y. H. Im, S. D. Markowitz, and Y. J. Bang. 2000. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 11: 159-168. (Pubitemid 30169736)
12. Teicher, B. A. 2007. Transforming growth factor-β and the immune response to malignant disease. Clin. Cancer Res. 13: 6247-6251. (Pubitemid 350075011)
13. Roberts, A. B., and L. M. Wakefield. 2003. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl. Acad. Sci. USA 100: 8621-8623. (Pubitemid 36899145)
14. Lu, S. L., D. Reh, A. G. Li, J. Woods, C. L. Corless, M. Kulesz-Martin, and X. J. Wang. 2004. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 64: 4405-4410.
15. Dasgupta, S., M. Bhattacharya-Chatterjee, B. W. O'Malley, Jr., and S. K. Chatterjee. 2005. Inhibition of NK cell activity through TGF-β1 by downregulation of NKG2D in a murine model of head and neck cancer. J. Immunol. 175: 5541-5550. (Pubitemid 41456442)
16. Dasgupta, S., M. Bhattacharya-Chatterjee, B. W. O'Malley, Jr., and S. K. Chatterjee. 2006. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-β1 secreted by the tumor cells. J. Cell. Biochem. 97: 1036-1051.
17. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
18. Ku, J. L., W. H. Kim, J. H. Lee, H. S. Park, K. H. Kim, M. W. Sung, and J. G. Park. 1999. Establishment and characterization of human laryngeal squamous cell carcinoma cell lines. Laryngoscope 109: 976-982. (Pubitemid 29269025)
19. Heo, D. S., C. Snyderman, S. M. Gollin, S. Pan, E. Walker, R. Deka, E. L. Barnes, J. T. Johnson, R. B. Herberman, and T. L. Whiteside. 1989. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 49: 5167-5175.
20. + regulatory T cells confer infectious tolerance in a TGF-β-dependent manner. J. Exp. Med. 205: 1975-1981.
21. Hagemann, T., J. Wilson, H. Kulbe, N. F. Li, D. A. Leinster, K. Charles, F. Klemm, T. Pukrop, C. Binder, and F. R. Balkwill. 2005. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J. Immunol. 175: 1197-1205. (Pubitemid 41095008)
22. Kulbe, H., T. Hagemann, P. W. Szlosarek, F. R. Balkwill, and J. L. Wilson. 2005. The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 65: 10355-10362. (Pubitemid 41743728)
23. Vila-del Sol, V., and M. Fresno. 2005. Involvement of TNF and NF-κB in the transcriptional control of cyclooxygenase-2 expression by IFN-γ in macrophages. J. Immunol. 174: 2825-2833.
24. Vila-del Sol, V., C. Punzon, and M. Fresno. 2008. IFN-γ-induced TNF-α expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. J. Immunol. 181: 4461-4470.
25. Khalil, N. 1999. TGF-β: from latent to active. Microbes Infect. 1: 1255-1263.
26. vβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328.
27. + regulatory T cell activity in both humans and mice. J. Immunol. 172: 834-842.
28. Fakhrai, H., O. Dorigo, D. L. Shawler, H. Lin, D. Mercola, K. L. Black, I. Royston, and R. E. Sobol. 1996. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93: 2909-2914. (Pubitemid 26114338)
29. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194: 629-644.
30. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202: 1075-1085.
31. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587.
32. Baker, K., P. Raut, and J. R. Jass. 2008. Colorectal cancer cells express functional cell surface-bound TGFβ. Int. J. Cancer 122: 1695-1700. (Pubitemid 351419064)
33. Broderick, L., and R. B. Bankert. 2006. Membrane-associated TGF-β1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J. Immunol. 177: 3082-3088. (Pubitemid 44277825)
34. Grainger, D. J., D. E. Mosedale, and J. C. Metcalfe. 2000. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev. 11: 133-145.
35. + T regulatory cells. J. Immunol. 177: 6091-6097.
36. Lim, D. S., J. H. Kim, D. S. Lee, C. H. Yoon, and Y. S. Bae. 2007. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol. Immunother. 56: 1817-1829.
37. Karin, M., Y. Cao, F. R. Greten, and Z. W. Li. 2002. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2: 301-310.
38. Leu, C. M., F. H. Wong, C. Chang, S. F. Huang, and C. P. Hu. 2003. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22: 7809-7818.
39. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51. (Pubitemid 46020826)
40. Niu, G., K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. Sinibaldi, D. Coppola, et al. 2002. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008. (Pubitemid 34270888)
41. Williams, L., L. Bradley, A. Smith, and B. Foxwell. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172: 567-576. (Pubitemid 38020514)
42. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550.
43. Patterson, S. G., S. Wei, X. Chen, D. A. Sallman, D. L. Gilvary, B. Zhong, J. Pow-Sang, T. Yeatman, and J. Y. Djeu. 2006. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25: 6113-6122.
44. Bui, J. D., L. N. Carayannopoulos, L. L. Lanier, W. M. Yokoyama, and R. D. Schreiber. 2006. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176: 905-913.
45. Robinson, C. M., P. T. Hale, and J. M. Carlin. 2006. NF-κB activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-γ and tumor necrosis factor-α. Cytokine 35: 53-61.
46. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179. (Pubitemid 351430364)
47. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
48. Hanada, T., T. Kobayashi, T. Chinen, K. Saeki, H. Takaki, K. Koga, Y. Minoda, T. Sanada, T. Yoshioka, H. Mimata, S. Kato, and A. Yoshimura. 2006. IFNα-dependent, spontaneous development of colorectal carcinomas in SOCS-1-deficient mice. J. Exp. Med. 203: 1391-1397. (Pubitemid 43877600)